Neuroscience
Antipsychotic
100%
In Vivo
74%
Olanzapine
64%
Brain
60%
Dopamine
43%
Synaptic Vesicle
38%
Magnetic Resonance Imaging
31%
Clozapine
30%
Positron Emission Tomography
29%
Hippocampus
26%
Striatum
19%
Dopaminergic
19%
Anterior Cingulate Cortex
19%
Ketamine
19%
Gray Matter Volume
14%
Amisulpride
13%
Ethnicity
13%
Cholesterol
13%
Putamen
13%
Midbrain
12%
Body Mass Index
11%
Atypical Antipsychotic
11%
Randomized Controlled Trial
11%
Parkinson's Disease
10%
Neuron
10%
Cerebellum
10%
Frontal Lobe
9%
Antidepressant
9%
N-Acetylaspartic Acid
9%
Nuclear Magnetic Resonance Spectroscopy
9%
Serotonin
9%
Brain Imaging
9%
Adenosine A2A Receptor
9%
Risperidone
9%
Dopamine Receptor D1
9%
Neuroligin
9%
D2 Antagonists
9%
Treatment of Schizophrenia
8%
Lurasidone
7%
Nucleus Accumbens
7%
Glycogen Synthase Kinase 3
6%
5-HT Receptor
5%
Phencyclidine
5%
Prolactin
5%
Temporal Lobe
5%
Medicine and Dentistry
Therapeutic Procedure
30%
Ketamine
29%
Antipsychotics
24%
Dopamine Metabolism
23%
Patient
22%
Human
22%
Side Effect
19%
Fluorine-18
19%
Association
19%
Network Meta-Analysis
19%
Systematic Review
19%
Clozapine
19%
Symptom
14%
Regulatory Mechanism
11%
Body Mass Index
11%
DOPA
9%
Molecular Imaging
9%
Pathophysiology
9%
Psychiatrist
9%
Midbrain
9%
Male
9%
Radioactive Tracer
8%
Drug Administration Route
8%
Health
8%
Lurasidone
7%
Water-Electrolyte Imbalance
7%
Randomized Controlled Trial
7%
Gender
5%
Brain
5%
Analysis
5%
Stimulation
5%
Pharmacology, Toxicology and Pharmaceutical Science
Antipsychotic
78%
Olanzapine
26%
Animal
22%
Schizophrenia
16%
Atypical Antipsychotics
11%
Stepholidine
9%
Rodent
9%
Risperidone
9%
Aripiprazole
8%